TCRX (STOCKS)
TScan Therapeutics, Inc. Common Stock
$0.924200
+0.012100 (+1.33%)
Prev close: $0.912100
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Gavin MacBeath
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $62.29M
- Employees
- 210
- P/E (TTM)
- -0.99
- P/B (TTM)
- 0.57
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
7
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.22 | $-0.18 | -0.0446 | -25.43% |
|
Dec 2025 (Q4)
|
$-0.18 | $-0.25 | +0.0660 | +26.83% |
|
Sep 2025 (Q3)
|
$-0.28 | $-0.30 | +0.0212 | +7.04% |
|
Jun 2025 (Q2)
|
$-0.28 | $-0.29 | +0.0062 | +2.17% |
Financial Statements
| Revenues | $9.14M |
| Benefits Costs and Expenses | $55.19M |
| Costs And Expenses | $136.48M |
| Operating Expenses | $137.84M |
| Research and Development | $106.27M |
| Other Operating Expenses | $28.67M |
| Operating Income/Loss | -$128.70M |
| Income/Loss From Continuing Operations After Tax | -$124.31M |
| Income/Loss From Continuing Operations Before Tax | -$46.06M |
| Interest Expense, Operating | $2.78M |
| Net Income/Loss | -$124.31M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$124.31M |
| Net Income/Loss Available To Common Stockholders, Basic | -$124.31M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.96 |
| Diluted Earnings Per Share | -$0.96 |
| Basic Average Shares | 389,508,283 |
| Diluted Average Shares | 389,508,283 |
| Assets | $201.99M |
| Current Assets | $132.77M |
| Noncurrent Assets | $69.23M |
| Fixed Assets | $8.12M |
| Other Non-current Assets | $61.11M |
| Liabilities | $105.07M |
| Current Liabilities | $19.97M |
| Accounts Payable | $2.30M |
| Wages | $4.76M |
| Other Current Liabilities | $12.91M |
| Noncurrent Liabilities | $85.10M |
| Long-term Debt | $32.65M |
| Other Non-current Liabilities | $52.45M |
| Equity | $96.92M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $96.92M |
| Liabilities And Equity | $201.99M |
| Net Cash Flow From Operating Activities | -$122.01M |
| Net Cash Flow From Operating Activities, Continuing | -$122.01M |
| Net Cash Flow From Investing Activities | $95.77M |
| Net Cash Flow From Investing Activities, Continuing | $95.77M |
| Net Cash Flow From Financing Activities | $24.54M |
| Net Cash Flow From Financing Activities, Continuing | $24.54M |
| Net Cash Flow | -$1.70M |
| Net Cash Flow, Continuing | -$1.70M |
| Comprehensive Income/Loss | -$124.30M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$124.30M |
| Other Comprehensive Income/Loss | -$72.66M |